Get the Stockscreener App
55.62
0.54%
0.30
After Hours:
55.62
Haemonetics Corp stock is traded at $55.62, with a volume of 693.23K.
It is up +0.54% in the last 24 hours and down -2.13% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$55.32
Open:
$55.85
24h Volume:
693.23K
Relative Volume:
0.86
Market Cap:
$2.58B
Revenue:
$1.32B
Net Income/Loss:
$175.44M
P/E Ratio:
15.28
EPS:
3.6395
Net Cash Flow:
$308.08M
1W Performance:
-7.05%
1M Performance:
-2.13%
6M Performance:
+9.66%
1Y Performance:
-10.99%
1-Day Range:
$54.92
$56.38
1-Week Range:
$54.92
$60.72
52-Week Range:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
55.62 | 2.57B | 1.32B | 175.44M | 308.08M | 3.6395 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | Needham | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Haemonetics to Present at Bank of America 2026 Healthcare Conference - PR Newswire
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Competitive Market Landscape - Markets Mojo
Is It Time To Reassess Haemonetics (HAE) After Recent Share Price Swings? - simplywall.st
MSN Money - MSN
Earnings Preview: Haemonetics to Report Financial Results Pre-market on May 07 - 富途牛牛
Haemonetics Announces Upcoming Departure of Longtime Board Director - TipRanks
Haemonetics (HAE) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Vanguard reports 2.60M-share stake in Haemonetics (HAE) via Schedule 13G - Stock Titan
North Peak Capital Management, LLC's Haemonetics Corp(HAE) Holding History - GuruFocus
Will VASCADE MVP XL’s Expanded FDA Labeling Shift Haemonetics’ (HAE) Electrophysiology Growth Narrative - Yahoo Finance
Skylands Capital LLC Sells 44,894 Shares of Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Challenges - Markets Mojo
Will VASCADE MVP XL’s Expanded FDA Labeling and Study Data Change Haemonetics' (HAE) Interventional Narrative? - simplywall.st
Riverwater Sees Haemonetics Volatility As Plasma Gains Test Execution - simplywall.st
Peregrine Capital Management LLC Invests $2.29 Million in Haemonetics Corporation $HAE - MarketBeat
New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures - PR Newswire
574-patient study reports 0% bleeding with Haemonetics closure device - Stock Titan
Riverwater Partners Analyzes Haemonetics Performance in Q1 2026 Letter - HarianBasis.co
Boston Trust Walden Corp Sells 376,040 Shares of Haemonetics Corporation $HAE - MarketBeat
Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation - Yahoo Finance
Haemonetics Corp stock (US4041191090): Why mobile-first Discover changes matter more now for medtech - AD HOC NEWS
Is Haemonetics (HAE) Using VASCADE MVP XL’s Expanded FDA Label To Deepen Its Moat? - simplywall.st
Assessing Haemonetics (HAE) Valuation After Recent Share Price Rebound And Discount To DCF Estimate - simplywall.st
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Mizuho Adjusts Haemonetics Corporation (HAE) Estimates in Sector-Wide Review - Insider Monkey
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
Haemonetics Corp stock (US4041191090): Why its steady focus on blood management innovation matters m - AD HOC NEWS
A Look at Haemonetics Corp (HAE) After 3.4% Gain -- GF Value $86 - GuruFocus
HAE Maintained by Mizuho -- Price Target Lowered to $70 - GuruFocus
Haemonetics price target lowered to $84 from $88 at BTIG - TipRanks
Haemonetics price target lowered to $70 from $80 at Mizuho - TipRanks
Blood Bag Market Is Going to Boom| Haemonetics Corporation • Grifols S.A. • Macopharma - openPR.com
Q3 2026 Haemonetics Corp Earnings Call Transcript - GuruFocus
Q2 2026 Haemonetics Corp Earnings Call Transcript - GuruFocus
Haemonetics Corporation (NYSE:HAE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Cuts Target Price to $64 - 富途牛牛
Haemonetics (HAE) Is Up 5.7% After FDA Expands VASCADE MVP XL Labeling for Larger EP Sheaths - simplywall.st
HAE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Haemonetics price target lowered to $64 from $70 at Citi - TipRanks
Is It Time To Reassess Haemonetics (HAE) After Recent Share Price Weakness? - simplywall.st
Can Haemonetics Corporation (HAE) Stock Rebound in 2026 | Price at $57.66, Up 1.46%Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Harbor Capital Advisors Inc. Sells 22,228 Shares of Haemonetics Corporation $HAE - marketbeat.com
HAE PE Ratio & Valuation, Is HAE Overvalued - Intellectia AI
Haemonetics Corporation (HAE) Stock forecasts - Yahoo Finance UK
Haemonetics will post earnings at 6 a.m., then take questions at 8 - Stock Titan
Is It Time To Reassess Haemonetics (HAE) After Prolonged Share Price Weakness - Yahoo Finance
Allspring Global Investments Holdings LLC Sells 121,063 Shares of Haemonetics Corporation $HAE - MarketBeat
Avantis U.S. Small Cap Equity Fund's Haemonetics Corp(HAE) Holding History - GuruFocus
Automatic Blood Bag Tube Stripper Market Is Going to Boom | Terumo - openPR.com
BTIG Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $88 - 富途牛牛
Haemonetics: FDA Label Expansion and New Product Launches Poised to Reignite Vascular Closure Growth by FY27 - TipRanks
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):